Quantum BioPharma

11/28/2025

Breakthroughs in MS don’t happen by accident — they happen when someone finally looks at the biology differently.

Most treatments in MS still revolve around the autoimmune narrative. But the science is shifting.
Demyelination has a biochemical signature: citrullination.

When myelin proteins become over-citrullinated, the sheath weakens, repair fails, and disease progression accelerates.

That’s why Lucid-MS stands out. It’s a new chemical entity built around the neurodegenerative side of MS — the part traditional drugs don’t touch.

Strong research deserves a fair environment to advance.

MS patients need real innovation. And the biology behind this one is worth paying attention to.

Learn More at https://quantumbiopharma.com/lucid-ms

$QNTM

11/27/2025

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

Thank you CTV News & Reporter Jon Woodward for the extensive coverage on these topics.

https://www.globenewswire.com/news-release/2025/11/27/3195939/0/en/Award-winning-Investigative-News-Program-W5-Airs-Part-2-of-3-part-Television-Series-on-Alleged-Stock-Market-Manipulation-of-Quantum-Biopharma-Involving-Two-of-Canada-s-Largest-Bank.html

$QNTM

11/27/2025

Thanks CTV News & W5's Investigative Journalism for taking the time to cover Quantum BioPharma’s story and for digging deeply into the alleged market-manipulation issues. $QNTM

W5's Jon Woodward () investigates the rise of stock spoofing and the push within Canada for steeper penalties to take the profit out of the rapidly evolving tactic.

$QNTM

11/27/2025

CTV News Tik Tok Coverage on Quantum Biopharma $QNTM talking about MS and Spoofing allegations.

https://vt.tiktok.com/ZSfmjC94t/

11/26/2025

Did 'stock spoofing' nearly sink a Toronto-based company's promising MS treatment?

W5's Jon Woodward investigates 'stock spoofing,' a market manipulation tactic that Quantum BioPharma claims nearly wiped out the company's share price.Subscr...

11/26/2025

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

https://www.globenewswire.com/news-release/2025/11/25/3194699/0/en/quantum-biopharma-s-usd-700-million-lawsuit-alleging-stock-market-manipulation-subject-of-3-part-series-investigative-news-program-w5.html

$QNTM

11/26/2025

CTV National News Inside Quantum BioPharma’s $700M Spoofing Case and MS Research Efforts

Live On-Air recording by CTV News () W5 investigative journalist Jon Woodward () exploring whether a Canadian company’s Multiple Sclerosis research was nearly derailed by alleged market manipulation.

https://youtu.be/-RX3-af3NGc

$QNTM

11/25/2025

CTV News CTV News Reporting: Quantum BioPharma $QNTM

Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?

This is part one of a W5 investigation into the phenomenon of “stock spoofing,” a market manipulation tactic that a Canadian biotech company says nearly derailed a promising medical treatment.

W5's Jon Woodward reports on the collapse of the share price of Toronto-based Quantum BioPharma and the $700M legal battle it sparked.

CTV News

11/25/2025

CTV News

Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?

This is part one of a W5 investigation into the phenomenon of “stock spoofing,” a market manipulation tactic that a Canadian biotech company says nearly derailed a promising medical treatment.

W5's Jon Woodward reports on the collapse of the share price of Toronto-based Quantum BioPharma and the $700M legal battle it sparked.

https://ctvnews.ca/business/article/was-a-canadian-companys-multiple-sclerosis-research-nearly-derailed-by-market-manipulation

$QNTM

Part one of a W5 investigation into the phenomenon of “stock spoofing,” a market manipulation tactic that a Canadian biotech company says nearly derailed a promising medical treatment.

11/21/2025

Lucid-MS is an experimental drug candidate exploring a distinct biological pathway tied to protein citrullination, a process implicated in myelin disruption in Multiple Sclerosis.

By modulating this pathway, Lucid-MS is being studied for its potential to support myelin integrity without suppressing the immune system.

This mechanism differs fundamentally from traditional anti-inflammatory approaches in MS, and preclinical research has reinforced its scientific potential.

$QNTM

11/17/2025

Listen to Sim Cha’s Story as she describes how she was affected by the spoofing allegations , we thank every shareholder who has shared their story with us.

https://youtu.be/2_yyOCRUlbM?si=zyPdAw_sJMV-WOUU

My ambition to become a successful artist has faded away. I suffered a lot under stress and mental exhaustion - Sim Cha (Belgium) Quantum Biopharma NASDAQ: Q...

11/17/2025

Demyelination is the starting point for understanding Multiple Sclerosis.

When the insulation around axons breaks down, signals slow, misfire, or lose precision — disrupting how neural circuits coordinate together.

Myelin isn’t “supportive tissue.”
It’s core architecture.

It determines how reliably information moves across the nervous system.

Understanding demyelination → understanding MS.

Quantum BioPharma focused on the Neurodegenerative aspect of MS.

$QNTM